Skip to main content

Site notifications

AusPAR: Imfinzi

Australian Public Assessment Report
Device/Product Name
Imfinzi
Active ingredients
Durvalumab
AusPAR Date
Published
Submission Number
PM-2022-01573-1-4
Submission Type
Extension of indications
Decision
Approved

Help us improve this page